Franco Cavalli

Bellinzona, TI, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 92 publications

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.

Journal: Blood

Published: February 20, 2025

A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA.

A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA.

Journal: Blood

Published: October 23, 2024

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results.

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 19, 2024

World Oncology Forum amplifies its appeal in global fight against cancer.

World Oncology Forum amplifies its appeal in global fight against cancer.

Journal: The Lancet. Oncology

Published: December 04, 2023

IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.

IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.

Journal: Haematologica

Published: August 14, 2023

The educational contribution of the college of the European school of oncology (ESCO): A survey analysis of the first three years.

The educational contribution of the college of the European school of oncology (ESCO): A survey analysis of the first three years.

Journal: Critical reviews in oncology/hematology

Published: August 02, 2023

A first-in-class Wiskott-Aldrich syndrome protein activator with antitumor activity in hematologic cancers.

A first-in-class Wiskott-Aldrich syndrome protein activator with antitumor activity in hematologic cancers.

Journal: Haematologica

Published: December 31, 2022

Changing the landscape of European School of Oncology-European Society for Medical Oncology masterclasses in clinical oncology during the COVID-19 pandemic.

Changing the landscape of European School of Oncology-European Society for Medical Oncology masterclasses in clinical oncology during the COVID-19 pandemic.

Journal: Future oncology (London, England)

Published: June 20, 2022

Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia.

Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia.

Journal: Hematological oncology

Published: May 25, 2022

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.

Journal: Leukemia

Published: January 12, 2022

ESO's career development program (2002-2021): Presentation and evaluation.

ESO's career development program (2002-2021): Presentation and evaluation.

Journal: Critical reviews in oncology/hematology

Published: December 07, 2021

Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.

Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.

Journal: The Lancet. Haematology

Published: October 28, 2021

Showing 1-12 of 92

Last Updated: 09/26/2026